McGrath K, Hogan C, Hunt D, O'Malley C, Green N, Dauer R, Dalli A
Department of Diagnostic Haematology, Royal Melbourne Hospital, Parkville, Australia.
Br Heart J. 1995 Aug;74(2):122-3. doi: 10.1136/hrt.74.2.122.
To determine the development of titres of streptokinase (SK) neutralising antibodies after a single dose of SK, to establish when titres decrease to levels at which a second dose might be effective.
Analyses of blood samples taken from patients at intervals after SK administration.
Australian public hospital.
104 patients with acute myocardial infarction who were treated with SK and 27 controls who were not.
SK neutralising antibodies were measured once in each of the 27 controls and on 166 occasions in the 104 treated patients.
Titres of SK neutralising antibodies rose after SK administration but returned to control levels by 2 years.
SK might be effective again as a thrombolytic agent as early as 2 years after a single dose. These results are at variance with most previously published data and the reasons for this are not clear. Data evaluating patency rates after standard doses of streptokinase in patients with increased titres of neutralising antibodies are necessary before re-exposure to streptokinase can be recommended.
确定单次注射链激酶(SK)后SK中和抗体滴度的变化情况,以确定滴度何时降至第二次注射可能有效的水平。
对SK给药后不同时间间隔采集的患者血样进行分析。
澳大利亚公立医院。
104例接受SK治疗的急性心肌梗死患者和27例未接受治疗的对照者。
对27例对照者各检测1次SK中和抗体,对104例接受治疗的患者检测166次。
SK给药后SK中和抗体滴度升高,但2年后恢复至对照水平。
单次注射SK后最早2年,SK可能再次作为溶栓剂有效。这些结果与之前大多数已发表的数据不同,原因尚不清楚。在推荐再次使用链激酶之前,有必要评估中和抗体滴度升高的患者使用标准剂量链激酶后的血管通畅率数据。